However, a recent study which used tamoxifen, which also acts as a GPER1 agonist, in a mouse model of pancreatic cancer, found that this could modify the microenvironment and reduce desmoplasia, inflammation, and immune suppression in PDAC.46 Here, GPER1 is linked to familial pancreatic carcinoma.